Acute Lymphocytic Leukaemia Hagop Kantarjian

Hagop Kantarjian: In this phase 2 study, a convenient, fully-oral regimen was effective and safe in an older/unfit population with acute myeloid leukemia

 

Hagop Kantarjian, a Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, recently posted on X:

“In this phase 2 study, a convenient, fully-oral regimen was effective and safe in an older/unfit population with acute myeloid leukemia. ”

Source: Hagop Kantarjian/X

Acute Myeloid Leukemia AML cancer cedazuridine decitabine fully-oral regimen Hagop Kantarjian Hematology older/unfit population OncoDaily Oncology phase 2 study venetoclax